Trodelvy Trial Failure Sparks Debate on Chinese Clinical Research Validity

The Trodelvy trial, conducted by Merck (MRK) and Gilead (GILD), aimed to test the efficacy of this drug as a first-line treatment for non-small cell lung cancer. Unfortunately, the results did not meet the primary endpoints, sparking concerns about the validity of clinical research in China when applied to Western markets.

The trial included a large proportion of Chinese patients, which raises questions about how well the results can be translated to European or North American populations. Differences in genetic makeup, standard of care, diet, and patient selection criteria can all impact how a drug performs across different regions and populations.

This setback is significant for both Merck and Gilead, as they had positioned Trodelvy as a potential key therapy in one of the world's largest oncology markets. The failed trial data will likely intensify discussions among oncologists, regulators, and investors about the reliability of clinical trial data generated in China.